Jazz Pharmaceuticals plc — Director's Dealing 2017

Mar 8, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2017-03-06

Reporting Person: Treacy Paul (SVP, Technical Operations)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-03-06	Ordinary Shares	S	355	$131.9745	Disposed	18108	Direct
2017-03-06	Ordinary Shares	S	529	$131.9749	Disposed	17579	Direct

Footnotes

F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $131.4935 to $131.9800. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to

provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $131.5330 to $131.9800. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to

provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.